反射，反射
About反射
31 articles about Reflexion
-
1平台Smilow Cancer Hospital at Yale New Haven 3/1/2023 RefleXion Medical，Inc.，a therapeutic oncology company，announced the installation of its RefleXion ® X1platform at Smilow Cancer Hospital，part of Yale New Haven Health，Connecticut’s largest healthcare system。 -
Reflexion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022 10/20/2022 反射，反射 ® Medical，atherapeutic oncology company pioneering biology-guided radiotherapy*（BgRT）asanew modality for treating all stages of cancer，today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation Amering the Oncatition TRO） 2022 Annual Meeting，Oct.23-26，in San Antonio。 -
Reflexion Announces14 Medical Physics Investigations at 2022 AAPM Annual Meeting 7/11/2022 Oral presentation evaluating feasibility of BgRT using long-lived immune PET tracer awarded Best in Physics。 -
Reflexion Announces Licensing Agreement with Mirada Medical to Advance Personalized Cancer Treatment 7/7/2022 Reflexion Medical，atherapeutic oncology company pioneering the use of biology-guided radiotherapy（BgRT）*forall stages of cancer，today announced annon-exclusive，worldwide licensing agreement with Mirada Medical。 -
扩展Cancer Treatment of 125M Debt Facility for Reflexion Announces Closing of$125M Debt Facility for Expanding Cancer Treatment 7/6/2022 Reflexion Medical，atherapeutic oncology company pioneering the use of biology-guided radiotherapy*for all stages of cancer，announced the closing of a$125M debt facility，of whic$55M is available immediately to repay the company’s existing$50M of debt。 -
专业Cancer Treatment为Telix and Reflexion Expand Partnership 6/10/2022 Telix Pharmaceuticals Limited（ASX:TLX，Telix，the Company）and Reflexion Medical，Inc.（Hayward，California，U.S.）（Reflexion）today announced the signing of aco-development and commercialisation agement，to expand the use of Telix's prostate cancer imaging agent，Illucx ®。 -
Reflexion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer 5/3/2022 Reflexion Medical announced the enrollment of the first patient into its PREMIER registry，a prospective，real-world evidence clinical outcomes registry for patients with all stages of cancer，at the University of Texas Southwestern in Dallas。 -
移动到：标记9-15 3/16/2022 The companies that got money this week were the ones investing in ambitious，future-looking technologies，such as RNA genomics，biochips and antibody-drug conjugates。 -
Twooncology-focused biotechnology firms generated a total of$247 million in additional funding to support their respective research and development effor cancer treatment。 -
Reflexion Raises$80 Million to Broaden Cancer Treatment Options 3/10/2022 Reflexion Medical，atherapeutic oncology company pioneering the use of biology-guided radiotherapy*forall stages of cancer，announced the close of an$80million equity financing。 -
Lung Cancer Treatment Reflexion Receives Breakthrough Device Designation for Lung Cancer Treatment 12/1/2021 Reflexion Medical，Inc.，atherapeutic oncology company，today announced that the U.S.Food and Drug Administration（FDA）has granted the company Breakthrough Device Designation forits biology-guided radiotherapy*（BgRT）foruse in treating lung tumors。 -
Reflexion Highlights New Cancer Treatment Research at ASTRO 2021 10/21/2021 Reflexion Medical，today announced multiple clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology（ASTRO）2021 Annual Meeting，Oct.24-27，in Chicago。 -
Reflexion Announces Newly Formed Scientific Advisory Board 10/19/2021 Reflexion Medical，atherapeutic oncology company pioneering biology-guided radiotherapy*asanew modality for treating all stages of cancer，announced the formation of a10-member Scientific Advisory Board。 -
Reflexion Expands Commercial Reach With Sale to Texas Cancer Center 7/21/2021 RefleXion Medical，Inc.，atherapeutic oncology company pioneering biology-guided radiotherapy*asanew modality that will one day treat all stages of cancer，announced the sale of its RefleXion ™，™ X1 machine to The Center for Cancer and Blood Disorders，afree-standing cancer treatment center with15locations throughout northern Texas。 -
Reflexion Announces New Additions to Board of Directors and Appoints Audit Committee Chair 5/27/2021 RefleXion Medical，Inc.，atherapeutic oncology company pioneering biology-guided radiotherapy*（BgRT）asa new modality for treating all stages of cancer，today announced the appointment of three external directors to its board of directors，Renee Ryan，Rana Al-Hallaq，Phroed -
Reflexion Add Ally Bridge Group to Investor Syndicate 3/2/2021 Reflexion Medical，atherapeutic oncology company pioneering the use of biology-guided radiotherapy*for all stages of cancer，announced the successful completion of a$40million extension to its Series D financing，which combined with$110million raised in 2020，brings the total Series D financing to$150million。 -
RefleXion and HealthMyne Collaborate to User Patient's Tumor Data to Guide Cancer Therapy 1/7/2021 Reflexion Medical，atherapeutic oncology company pioneering biology-guided radiotherapy*（BgRT）asanew modality for treating all stages of cancer，and HealthMyne Inc。， an inno -
Reflexion Announces Multi System Agreement With Integrated Proton Solutions 11/16/2020 自由Standing Center Improve Accessibility to Sophistication Cancer Care for Local Communities -
Reflexion and Telix Pharmaceuticals Announce Strategic Collaboration for Treatment of High-Risk Cancers 7/8/2020 Reflexion Medical，atherapeutic oncology company pioneering biology-guided radiotherapy*（BgRT）asanew modality for treating all stages of cancer，and Telix Pharmaceuticals Limited（ASX:TLX），ardiopharmaceutical company developin molecularly-targeted radiation（MTR）products， today announced a strategic collaboration to investigate the clinical utility of combining the companies’ -
Reflexion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA ® 中央停车场 5/28/2020 Reflexion Medical，atherapeutic oncology company pioneering biology-guided radiotherapy*（BgRT）for treating all stages of cancer，today announced a clinical collaboration with Merck（known as MSD outside the U.S.and Canada）to evaluate the safety and efficy of KEYTRUDA ® （pembrolizumab），Merck’santi-PD-1therapy，in combination with BgRT in multiple late-stage cancers，including non-small cell lung cancer（NSCLC）